New treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and motor neuron disease (MND) could be unlocked thanks to microscopic medicines developed by researchers at the University ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

A simple test could detect Alzheimer's years before symptoms appear, offering hope for earlier intervention and treatment.

Smith Could a simple blood test predict your risk of getting dementia years, or even decades, before you experience memory ...

The NHS spending watchdog must look again at its decision after drug manufacturers successfully appealed against Nice's ruling that the treatments were not cost-effective ...

Donanemab and lecanemab have been shown to delay progression from mild to moderate Alzheimer's by up to six months but are ...

Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed ...

Results illustrate how NetraMark’s advanced AI can potentially support precision enrichment strategies in future trials ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease.

What has long been interpreted as permanent and irreversible vascular damage may not be exclusively so. In people with Down syndrome—one of the most robust populations for studying Alzheimer's disease ...

STOCKHOLM, SE / ACCESS Newswire / March 19, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, fo ...